#ASH18 – Coming to a Close

Teresa Miceli |

The American Society of Hematology (#ASH18) annual meeting is has come to an end. Monday has been traditionally known as “Myeloma Madness Monday.” This year was no different. Oral sessions included topics on the combination therapies, #CAR-T and #BiTE (Bispecific T-cell Engager) therapy. Other potential new agents in #myeloma, like venetoclax, selinexor and isatuximab, were […]

Recollections of the 60th Annual ASH Meeting and Expo

Jim Omel |

ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

ASH 2018: My Final Thoughts, Links, and Thanks!

Robin Tuohy |

While this year’s ASH had 939 abstracts about multiple myeloma, I agree with Linda Huguelet that this year was a building year, and no real blockbusters. However, and it’s a big however, because there are many future blockbusters expected from the early phase 1 trials as they continue forward, I encourage that you pay attention […]

Day 3 – Saving the Best for Last

Jack Aiello |

December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]

Lights – Camera – ASH!

Teresa Miceli |

The 60th Annual American Society of Hematology (#IMFASH18 #ASH18) meeting will return to San Diego, CA.  With the return to a California venue, and as a member of the International Myeloma Foundation’s (IMFs) Support Group Leader (SGL) contingency, I think in Hollywood terms. For many, the Fall season is marked by the annual Prime Time Emmy […]

How Do Patients Learn at ASH?

Jack Aiello |

Soon I’ll be off to San Diego, the site of this year’s American Society of Hematology (ASH) conference. ASH is all about blood cancers (leukemia, lymphoma, multiple myeloma), and there are nearly 700 oral presentations and posters on myeloma alone. I’m so grateful to the International Myeloma Foundation (IMF) and their sponsors for sending me, […]